Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 3/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065728 | 0.83 | ALDH1A1 (0.37) | HMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL9283567 | 0.83 | ALDH1A1 (0.37) | HMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL10024024 | 0.83 | ALDH1A1 (0.37) | HMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL6956315 | 0.73 | PRMT5 (0.47) | — | |
| SCHEMBL9287478 | 0.73 | TOP2A (0.39) | HMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL9269812 | 0.72 | HMGCR (0.38) | HMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL2167968 | 0.72 | HMGCR (0.36) | HMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL10024054 | 0.72 | HMGCR (0.38) | HMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL4643619 | 0.72 | HMGCR (0.38) | HMGCRHDAC1HDAC2HDAC6 | |
| SCHEMBL4440967 | 0.72 | HMGCR (0.38) | HMGCRHDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148550-B2 | selected from fluvastatin, rosuvastatin, cerivastatin, glenvastatin or atorvastatin, by reduction or lactonization of chemical intermediate compounds, then hydrogenation, decyclization and deprotection of hydroxy groups | RATIOPHARM GMBH (DE) | 2012-04-03 | — | — | US | disclosed |
| US-20080249306-A1 | Method for the Production of Statins | RATIOPHARM GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249306-A1 | Method for the Production of Statins | HMGCR, COASY, PCSK9 | HMGCR 1/4885HDAC1 1834/4885HDAC2 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.